A022104 - The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer

Principal Investigator

Kathryn Hourdequin

Study Number

STUDY02001880

Summary

A022104 - This study is for patients who have advanced rectal cancer. The study hopes to determine if adding an additional drug (irinotecan) to the current standard treatments of FOLFOX or CAPOX (usual treatment) can increase how effective the drugs treat the cancer when given in combination in combination with long-course chemoradiation (usual treatment). There are 2 groups in this study with 156 patients expected in each. One group will receive one of the usual treatments and the other group will receive irinotecanin combination with FOLFOX. Patients will receive treatment for about 7.5 months and then have follow up by the study team for 5 years.

Phase

II

Contact

Michael Christina Crowley Seymour

Available at the following location(s)

• Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms